Recent articles
Should Amyris Split Into 2 Companies?
Unlocking the true value of the company's consumer portfolio might require a big, bold decision.
Here's Why Teva Pharmaceutical Fell as Much as 15.4% Today
The United States is suing the drugmaker. Again.
Here's Why Unity Biotechnology Is Getting Crushed Today
The development-stage biopharma announced disappointing results from a clinical trial.
Personalis Turns to Liquid Biopsies for Growth. Will It Work?
The company, which leans on one customer for 76% of revenue, desperately needs to diversify its customer base.
Twist Bioscience Is Rapidly Growing Its Customer Base. Can It Turn a Profit?
The DNA synthesis leader is rapidly expanding its product offerings, but losses continue to grow. Maybe it doesn't matter after all.
Here's Why Omeros Fell Over 13% Today
The biopharma announced the pricing of a public offering of common stock and debt offering.
Here's Why Personalis Fell as Much as 13.8% Today
The genomics company announced a public offering of common stock.
Coherus BioSciences Keeps Proving Wall Street Wrong
The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
Mesoblast Plunges as FDA Questions Cell-Therapy Manufacturing
The Australian stem-cell company will face some pointed questions from regulators about how it manufactures stem cells.
Codexis Dodges Coronavirus Slowdown in Q2
R&D revenue from two customers helped the business to offset weakness from the coronavirus pandemic.
Albemarle Reports 41% Decline in Q2 Net Income
Investors will have to expect much of the same in the second half of the year.
Amyris Reports Its Largest First-Half Operating Loss Since 2012
A growing balance of deferred cost of product revenue suggests business fundamentals might be significantly worse than reported.
Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today
A rumored merger has investors excited, although details are scarce.
What to Watch When Twist Bioscience Reports Fiscal Q3 Results
Can the company possibly live up to its lofty market valuation?
Renewable Energy Group Posts Surprise Q2 Profit
The biomass-based diesel manufacturer smashed through its own lowly expectations thanks to a boost from state and federal incentives.
Does the Hydrogen Economy Have a Pipeline Problem?
Manufacturing hydrogen from renewable energy sounds great, but there are significant limitations to transporting hydrogen fuels.
NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound
The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.
What to Watch When Albemarle Reports Q2 Earnings
The specialty chemicals manufacturer is expected to struggle in 2020, but it has undertaken significant efforts to preserve long-term business fundamentals.
What to Watch When Renewable Energy Group Reports
The renewable fuels manufacturer is contending with a historic slowdown in demand for transportation fuels. Are diesel fuels more insulated from uncertainty?
Repligen Reports Record Quarter, Increases 2020 Guidance
The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.